Friday, July 10, 2026
🇺🇸 FDA

pharma · Muscle-invasive bladder cancer (MIBC) · Acute ischaemic stroke due to basilar artery occlusion.

Tour Hekla

Tour Hekla drug portfolio — 71 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

Website Investor relations
Puteaux, Ile de France 92800, FR HQ
6 Employees
EMA registrant Type
Company details
Status
Public
HQ
Puteaux, Ile de France 92800, FR
Employees
6
Programs
27
Drugs
71
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Drug Pipeline

Tour Hekla pipeline

Portfolio lens on 71 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.

Tour Hekla drug portfolio — 71 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

Drug portfolio

71 compounds

  2. adrenaline (epinephrine)

    Development asset linked to Tour Hekla in public FDA and regional records. Molecular target: Adrenergic receptor.

    Target
    Adrenergic receptor
    Mechanism
    Adrenergic receptor agonist

  3. amikacin

    Antiinfectives for systemic use (J01)

    Antiinfectives for systemic use (J01) compound in Tour Hekla's portfolio.

  5. anti-

    Development asset linked to Tour Hekla in public FDA and regional records.

  6. antibiotics

    Development asset linked to Tour Hekla in public FDA and regional records.

  7. atezolizumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Programmed cell death 1 ligand 1.

    Target
    Programmed cell death 1 ligand 1
    Mechanism
    Programmed cell death 1 ligand 1 inhibitor

  8. bevacizumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Vascular endothelial growth factor A, long form.

    Target
    Vascular endothelial growth factor A, long form
    Mechanism
    Vascular endothelial growth factor A inhibitor

  9. calcium

    US regulatory status: approved.

  10. carisoprodol

    US regulatory status: approved. Mechanism: Unknown.

    Mechanism
    Unknown

  11. carvedilol

    US regulatory status: approved. Molecular target: Adrenergic receptor alpha-1.

    Target
    Adrenergic receptor alpha-1
    Mechanism
    Adrenergic receptor beta antagonist

  12. caspofungin

    Antiinfectives for systemic use (J02)

    Antiinfectives for systemic use (J02) compound in Tour Hekla's portfolio.

  13. chloride

    Development asset linked to Tour Hekla in public FDA and regional records.

  14. control

    Development asset linked to Tour Hekla in public FDA and regional records.

  15. conventional

    Development asset linked to Tour Hekla in public FDA and regional records.

  16. covid-19 mrna vaccine

    Antiinfectives for systemic use (J07)

    Antiinfectives for systemic use (J07) compound in Tour Hekla's portfolio. Molecular target: Spike glycoprotein.

    Target
    Spike glycoprotein
    Mechanism
    Spike glycoprotein vaccine antigen

  17. dexmedetomidine

    Nervous system (N05)

    Nervous system (N05) compound in Tour Hekla's portfolio. Mechanism: Adrenergic receptor alpha-2 agonist.

    Mechanism
    Adrenergic receptor alpha-2 agonist

  18. diclofenac

    US regulatory status: approved. Molecular target: Cyclooxygenase.

    Target
    Cyclooxygenase
    Mechanism
    Cyclooxygenase inhibitor

  19. dose

    Development asset linked to Tour Hekla in public FDA and regional records.

  21. hexachlorophene

    US regulatory status: approved. Molecular target: Enoyl-[acyl-carrier-protein] reductase [NADH] FabI.

    Target
    Enoyl-[acyl-carrier-protein] reductase [NADH] FabI
    Mechanism
    Bacterial enoyl-[acyl-carrier-protein] reductase inhibitor

  22. hydrogen

    Development asset linked to Tour Hekla in public FDA and regional records.

  23. hypromellose

    Development asset linked to Tour Hekla in public FDA and regional records.

  24. induction

    Development asset linked to Tour Hekla in public FDA and regional records.

  25. infusion

    Development asset linked to Tour Hekla in public FDA and regional records.

  26. inhalation

    Development asset linked to Tour Hekla in public FDA and regional records.

  27. injectable

    Development asset linked to Tour Hekla in public FDA and regional records.

  28. injection

    Development asset linked to Tour Hekla in public FDA and regional records.

  29. intensive

    Development asset linked to Tour Hekla in public FDA and regional records.

  30. iohexol

    US regulatory status: approved. Mechanism: Diagnostic agent.

    Mechanism
    Diagnostic agent

  31. ipilimumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Cytotoxic T-lymphocyte protein 4.

    Target
    Cytotoxic T-lymphocyte protein 4
    Mechanism
    Cytotoxic T-lymphocyte protein 4 inhibitor

  32. mannitol

    Respiratory system (R05)

    US regulatory status: approved. Mechanism: Unknown.

    Mechanism
    Unknown

  34. methylphenidate hydrochloride

    Nervous system (N06)

    US regulatory status: approved. Molecular target: Sodium-dependent dopamine transporter.

    Target
    Sodium-dependent dopamine transporter
    Mechanism
    Dopamine transporter inhibitor

  35. midazolam

    Nervous system (N05)

    US regulatory status: approved. Molecular target: GABA-A receptor; anion channel.

    Target
    GABA-A receptor; anion channel
    Mechanism
    GABA-A receptor; anion channel positive allosteric modulator

  36. monohydrate

    Development asset linked to Tour Hekla in public FDA and regional records.

  37. morphine

    Development asset linked to Tour Hekla in public FDA and regional records. Mechanism: Mu opioid receptor agonist.

    Mechanism
    Mu opioid receptor agonist

  38. nivolumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Programmed cell death protein 1.

    Target
    Programmed cell death protein 1
    Mechanism
    Programmed cell death protein 1 inhibitor

  39. orlistat

    Alimentary tract and metabolism (A08)

    US regulatory status: approved. Molecular target: Gastric triacylglycerol lipase.

    Target
    Gastric triacylglycerol lipase
    Mechanism
    Pancreatic lipase inhibitor

  40. oxygen

    US regulatory status: approved. Mechanism: Essential for cellular homeostasis.

    Mechanism
    Essential for cellular homeostasis

  41. oxytocin

    US regulatory status: approved. Molecular target: Oxytocin receptor.

    Target
    Oxytocin receptor
    Mechanism
    Oxytocin receptor agonist

  42. penicillin g potassium

    US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.

    Target
    Bacterial penicillin-binding protein
    Mechanism
    Bacterial penicillin-binding protein inhibitor

  43. phenoxymethylpenicillin

    Development asset linked to Tour Hekla in public FDA and regional records. Molecular target: Bacterial penicillin-binding protein.

    Target
    Bacterial penicillin-binding protein
    Mechanism
    Bacterial penicillin-binding protein inhibitor

  44. piperacetazine

    US regulatory status: approved. Molecular target: D(2) dopamine receptor.

    Target
    D(2) dopamine receptor
    Mechanism
    Dopamine D2 receptor antagonist

  45. placebo

    Development asset linked to Tour Hekla in public FDA and regional records.

  46. powder

    Development asset linked to Tour Hekla in public FDA and regional records.

  47. propranolol

    Cardiovascular system (C07)

    Cardiovascular system (C07) compound in Tour Hekla's portfolio. Mechanism: Beta-1 adrenergic receptor antagonist.

    Mechanism
    Beta-1 adrenergic receptor antagonist

  48. protocol

    Development asset linked to Tour Hekla in public FDA and regional records.

  49. rifampicin

    Development asset linked to Tour Hekla in public FDA and regional records. Molecular target: Bacterial DNA-directed RNA polymerase.

    Target
    Bacterial DNA-directed RNA polymerase
    Mechanism
    Bacterial DNA-directed RNA polymerase inhibitor

  50. rifampin

    US regulatory status: approved. Molecular target: Bacterial DNA-directed RNA polymerase.

    Target
    Bacterial DNA-directed RNA polymerase
    Mechanism
    Bacterial DNA-directed RNA polymerase inhibitor

  51. rituximab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: B-lymphocyte antigen CD20.

    Target
    B-lymphocyte antigen CD20
    Mechanism
    B-lymphocyte antigen CD20 binding agent

  52. rivaroxaban

    Blood and blood forming organs (B01)

    US regulatory status: approved. Molecular target: Coagulation factor X.

    Target
    Coagulation factor X
    Mechanism
    Coagulation factor X inhibitor

  53. sirolimus

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: Peptidyl-prolyl cis-trans isomerase FKBP1A.

    Target
    Peptidyl-prolyl cis-trans isomerase FKBP1A
    Mechanism
    FK506-binding protein 1A inhibitor

  55. solution

    Development asset linked to Tour Hekla in public FDA and regional records.

  56. solvent

    Development asset linked to Tour Hekla in public FDA and regional records.

  57. standard

    Development asset linked to Tour Hekla in public FDA and regional records.

  58. starch

    Development asset linked to Tour Hekla in public FDA and regional records.

  59. stro-

    Development asset linked to Tour Hekla in public FDA and regional records.

  60. sulfamethoxazole

    US regulatory status: approved. Molecular target: Dihydropteroate synthase.

    Target
    Dihydropteroate synthase
    Mechanism
    Bacterial dihydropteroate synthase inhibitor

  61. suspension

    Development asset linked to Tour Hekla in public FDA and regional records.

  62. tablet

    Development asset linked to Tour Hekla in public FDA and regional records.

  63. tablets

    Development asset linked to Tour Hekla in public FDA and regional records.

  65. tenecteplase

    Blood and blood forming organs (B01)

    US regulatory status: approved. Molecular target: Tissue-type plasminogen activator.

    Target
    Tissue-type plasminogen activator
    Mechanism
    Tissue-type plasminogen activator exogenous protein

  66. therapy

    Development asset linked to Tour Hekla in public FDA and regional records.

  67. topiramate

    US regulatory status: approved. Molecular target: Carbonic anhydrase 2.

    Target
    Carbonic anhydrase 2
    Mechanism
    GABA-A receptor; anion channel positive modulator

  68. treatment

    Development asset linked to Tour Hekla in public FDA and regional records.

  69. trimethoprim

    US regulatory status: approved. Molecular target: Dihydrofolate reductase.

    Target
    Dihydrofolate reductase
    Mechanism
    Bacterial dihydrofolate reductase inhibitor

  70. usual

    Development asset linked to Tour Hekla in public FDA and regional records.

  71. vaccine

    Development asset linked to Tour Hekla in public FDA and regional records.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.